대한핵의학회지 (1967년~2009년)
Nucl Med Mol Imaging 2006;40(2)127~131
방사성 활막절제술
(Radiosynovectomy)
Author 김덕윤,
Deog Yoon Kim, M.D.
Affiliation 경희대학교 의과대학 핵의학교실
Department of Nuclear Medicine, Kyung Hee Unversity School of Medicine, Seoul, Korea
Abstract

Radiosynovectomy has been used as an effective treatment in patients with resistant synovitis after failure of long-term medication and intraarticular steroid injection. Although 90Y silicate/citrate, 186Re sulfide, and 169Er citrate were approved in Europe for the appropriate radiopharmaceuticals for radiosynovectomy, other radionuclides such as 32P-chromic phosphate, 165Dy-ferric hydroxide macroaggregate, 188Rh-microspheres, 153Sm-particulate, and 166Ho- ferric hydroxide macroaggregate have been used in many countries. Reported success rates range from 40% to 90% for the different joints and underlying disease. In Korea, 188Re-tin-colloid and 166Ho-chitosan complex are now using as the major radionuclides in radiosynovectomy with good clinical results. A study on radiation synovectomy using 188Re-tin-colloid for patients with Korean rheumatoid arthritis shows the treatment resulted in the improvement of arthritis and well tolerated. In our study, the radiosynovectomy with 166Ho-chitosan complex in 53 hemophilic patients markedly decreased intra-articular bleeding frequency and need for coagulation factor. This review inculdes general priciples in the application of radiosynovectomy and the clinical experience in Korea. (Nucl Med Mol Imaging 2006;40(2):127-131)

Keyword radionuclide therapy, radiosynovectomy, rheumatoid arthritis, hemophilia
Full text Article 4002127.pdf 4002127.pdf
(03121)서울시 종로구 지봉로 29 금호팔레스빌딩 1705호
TEL : 02-745-2040 FAX : 02-745-3833 E-mail : ksnm@ksnm.or.kr
Copyright 2012 by The Korean Society of Nuclear Medicine(KSNM)